Loading...
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
In order to evaluate the effect of topical and subconjunctival anti-vascular endothelial growth factor (anti-VEGF) therapy, Ranibizumab, Bevacizumab and Aflibercept as a therapy for corneal neovascularization (NV) treatment, the aim of this study was to review all data related to some of anti-VEGF a...
Saved in:
| Published in: | Saudi J Ophthalmol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Elsevier
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5436388/ https://ncbi.nlm.nih.gov/pubmed/28559722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.sjopt.2017.02.008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|